← Leaderboards
Laura L Koth
University Of California San Francisco
$7,443,241
Attributed
$10,969,931
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,969,931 · 8
By mechanism
R01$8,890,015 · 2
K08$608,850 · 1
U01$469,552 · 1
R56$386,250 · 1
R03$335,462 · 2
R34$279,802 · 1
Top collaborators
- Nabeel Hamzeh4 shared
- Sonia Leach4 shared
- Brian P O'Connor4 shared
- Joe G. N. Garcia3 shared
- Fracisco A Bonilla1 shared
- Charlotte Cunningham-Rundles1 shared
- Raif Salim Geha1 shared
- Katherne E Gundling1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Stephen L Hauser$36,073,865
- George Su$2,218,551
- David Krizaj$11,313,886
Others in their field
Top investigators on “Pulmonary Sarcoidosis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Wonder P. Drake · University Of Maryland Baltimore$5,745,903
- David R Moller · Johns Hopkins University$5,227,109
- Lisa A Maier · National Jewish Health$4,894,401
- Courtney Montgomery · Case Western Reserve University$4,710,488
- William N Rom · New York University School Of Medicine$4,154,069
Research focus
Pulmonary SarcoidosisSarcoidosisLungBloodOrganCohortLung DiseasesInflammationChronicFutureDisease ProgressionSeveritiesFollow-UpInterferonsToxic EffectEnrollmentUnited States National Institutes Of HealthThoracic RadiographyT-LymphocytePhenotypeResourcesRaceFrequenciesPathogenesis
Grant awards (28)
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$994,512
R01 · FY2025 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$128,372
R01 · FY2025 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$974,622
R01 · FY2024 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$208,277
R01 · FY2024 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$128,372
R01 · FY2024 · HL · contact PI
Longitudinal acquisition of immune signatures for pulmonary sarcoidosis - UMB DS$93,841
R01 · FY2024 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$1,059,451
R01 · FY2023 · HL · contact PI
The Impact of Environmental Exposures on Sarcoidosis Incidence and Mortality$101,570
R01 · FY2023 · HL · contact PI
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis$1,153,760
R01 · FY2022 · HL · contact PI
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary Sarcoidosis$992,527
R01 · FY2021 · HL
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary Sarcoidosis$999,912
R01 · FY2020 · HL
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary Sarcoidosis$1,004,873
R01 · FY2019 · HL
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary Sarcoidosis$1,049,926
R01 · FY2018 · HL
Interferon gamma-Producing Th17 Subsets: Major Contributors to "Th1" Diseases$79,250
R03 · FY2017 · AI · contact PI
Interferon gamma-Producing Th17 Subsets: Major Contributors to "Th1" Diseases$79,250
R03 · FY2016 · AI · contact PI
GLILD in CVID$279,802
R34 · FY2014 · AI
Genomic Phenotyping and Mechanisms in sarcoidosis and AAT$152,391
U01 · FY2014 · HL · contact PI
Genomic Phenotyping and Mechanisms in sarcoidosis and AAT$148,036
U01 · FY2013 · HL · contact PI
Genomic Phenotyping and Mechanisms in sarcoidosis and AAT$169,125
U01 · FY2012 · HL · contact PI
Immunophenotyping and Lymphocyte Effector Functions in Sarcoidosis$386,250
R56 · FY2010 · AI · contact PI
Effector function of natural killer T (NKT) cells in sarcoidosis$76,478
R03 · FY2010 · AI · contact PI
Effector function of natural killer T (NKT) cells in sarcoidosis$77,250
R03 · FY2009 · AI · contact PI
Effector function of natural killer T (NKT) cells in sarcoidosis$23,234
R03 · FY2009 · AI · contact PI
MCP-1 and TGFb in Macrophage Activation and Emphysema$121,770
K08 · FY2007 · HL · contact PI
MCP-1 and TGFb in Macrophage Activation and Emphysema$121,770
K08 · FY2006 · HL · contact PI
MCP-1 and TGFb in Macrophage Activation and Emphysema$121,770
K08 · FY2005 · HL
MCP-1 and TGFb in Macrophage Activation and Emphysema$121,770
K08 · FY2004 · HL
MCP-1 and TGFb in Macrophage Activation and Emphysema$121,770
K08 · FY2003 · HL